Skip to main content
Premium Trial:

Request an Annual Quote

Celera Splits Stock, Creates Tools with Neomorphic, Takes Stake in Chinese Co

Premium

R

OCKVILLE, Md.--Celera Genomics’ stock price continued its climb on news of a planned two-for-one split, along with the announcement that it and the Berkeley, Calif., genomics firm Neomorphic have developed a browser software application for accessing Celera’s genomic databases.

The browser has been designed to enable Celera and its customers to research the human and Drosophila genomes for medically relevant and commercially valuable genes in the context of a complete genome. The price of Celera’s stock closed more than $10 up at $226.375 on the day of the announcements, according to SunSpot, the Baltimore Sun’s online news service.

Separately, Celera has also taken over a 47.5 percent equity stake in Shanghai GeneCore BioTechnologies, a genomics service company, from Axys Pharmaceuticals. The Chinese company said it is involved in nucleotide synthesis, DNA sequencing, bioinformatics analysis, and mutation detection and has ongoing research collaborations with several Chinese government agencies and research institutes.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.